Purpose of review More than 80 susceptibility loci are now reported to show robust genetic association with systemic lupus erythematosus (SLE). The differential functional effects of the risk alleles for the majority of these loci remain to be defined. Here, we review current SLE association findings and the recent progress in the annotation of noncoding regions of the human genome as well as the new technologies and statistical methods that can be applied to further the understanding of SLE genetics.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease associated with a wide range of signs and symptoms varying among affected individuals and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and haematopoietic system. The population prevalence varies with ancestry, being more prevalent in non-European populations with a significant sex disparity towards women (6 : 1) during the years between menarche and menopause [1] . Although the exact cause of lupus is not fully understood, a strong genetic link has been identified through the application of family and large-scale genome-wide association studies (GWAS). The concordance rate in monozygotic twins (24%) is approximately 10 fold higher than in dizygotic twins (2%) [2, 3] . A recent study from Taiwan reported that the heritability was 43.9% and the proportion of phenotypic variance explained by shared and nonshared environmental factors was 25.8 and 30.3%, respectively, suggesting nonheritable factors may play a considerable role in disease pathogenesis [4] .
There are now more than 80 loci reported to be associated with the susceptibility of SLE. Here, we review current SLE association findings and the recent progress in the annotation of the noncoding region of the human genome as well as new 
INSIGHTS FROM GENOME-WIDE ASSOCIATION STUDIES
Genetic linkage analysis and candidate gene association studies identified several SLE susceptibility loci (e.g., HLA-DR2/DR3) [5] . Nevertheless, the advent and application of GWAS dramatically advanced knowledge of the genetic cause of SLE.
There have been seven SLE GWAS in European population [6-10,11 & ,12] , six Asian GWAS [13-17,18 & ], and one GWAS of Amerindian ancestry [19] , as well as subsequent meta-analysis and largescale replication studies [20, 21, 22 & ,23], published since 2008. Currently, 84 genetic loci are implicated as SLE risk ( Fig. 1 : The CIRCOS plot [24] and Supplementary Table 1 , http://links.lww.com/COR/A37), which, to avoid likely spurious associations, include genetic associations with a P value less than 5 Â 10
À8
tested in a total sample size of at least 1000 individuals. The interactive version of a continually updated resource with details on SLE associations can be access through the following link: http:// insidegen.com/insidegen-LUPUS-Associations.html.
With the caveat that the majority of mechanisms remain to be elucidated, it appears that the risk loci associated with SLE influence immune cell function. Although functional studies are designed with a-priori hypotheses in mind, key pathogenic pathways that are likely influenced by SLE-associated gene products include: immune complex processing and phagocytosis; DNA degradation, apoptosis, and clearance of cellular debris; neutrophil and monocytes signalling; Toll-like receptor and/or type I interferon signalling; nuclear factor kappa beta (NF-kb) activation; and B and T-cell function and signalling. Some genes associated with SLE may act through several pathways. For example, TNFAIP3, encoding the ubiquitin-editing enzyme A20, is a key regulator of NF-kb-derived proinflammatory responses, which is involved in both adaptive and innate immune pathways [25, 26] . These SLE susceptibility loci contain predominantly common (frequency of >0.1% in the general population) associated variants that have been confirmed among multiple ancestries, suggesting shared mechanisms in disease cause [27] [28] [29] .
European genome-wide association studies
The largest European GWAS of SLE conducted by our group [11 & ], comprised 7219 SLE cases and 15 991 controls of European decent, provided considerable power to detect disease risk loci. Notably, the study identified 43 susceptibility loci, 10 of which were novel loci: SPRED2, IKZF2, IL12A, TCF7-SKP1, DHCR7-NADSYN1, SH2B3, RAD51B, CIITA-SOCS1, PLD2, and CXorf21. One of the great challenges posed by interpreting GWAS data is determining the causal genes implicated by the genetic association data. As will be discussed below, we put some considerable effort into this process before naming the genes in the above list. Irrespective of the underlying causal genes, we can conclude that the heritability explained by the risk alleles mapped at these loci is 15.3%, which is a large increase over the 8.7% reported by So et al. [30] using the same measure.
Asian genome-wide association studies
An extensive large-scale fine mapping study using Immunochip conducted in 4478 SLE cases and 12 656 controls from six East Asian cohorts identified 10 novel loci [18 & ] in Asians, encompassing GTF2IRD1-GTF2I, DEF6, IL12B, TCF7, TERT, CD226, PCNXL3, RASGRP1, SYNGR1, and SIGLEC6. Some of these were previously reported to be associated in Europeans, for example, DEF6 and TCF7. The identification of these risk loci increased the explained heritability to 24% in Asian SLE. Nevertheless, the Immunochip was designed from predominant European genetic information and will, therefore, be less
KEY POINTS
The discovery of SLE-associated risk variants has accelerated in the past 2 years with huge sample size genome-wide and meta-analysis studies revealing novel loci in both coding and noncoding regions of the genome.
Expression quantitative trait loci mapping incorporating colocalization analysis of GWAS results help to identify the underlying causal genes.
The Encyclopedia of DNA elements, Roadmap, and Blueprint projects which annotate noncoding regions have created comprehensive maps of the human genome.
SLE-associated risk loci can be analysed bioinformatically, in the context of functional annotation to predict biological impact.
Functional validation is required for designating variants as 'causal variants', and facilitated by the availability of genome editing tools such as clustered regulatory interspaced short palindromic repeats technology to artificially create the variant in a model system relevant for disease.
informative and not represented genetic variation in Asian population so well as in Europeans [31] .
Trans ancestry meta analyses of genome-wide association studies ], that combined three GWAS from two ethnicities: Chinese (1659 cases and 3398 controls) and European (4044 cases and 6959 controls), found evidence of considerable commonality in terms of SLE association signals as well as mapping novel susceptibility loci, including CD45, IKBKE, LBH, LPP-TPRG1-AS1, ATXN1, BACH2, GTF2I, JAK2, RNASEH2C, and ZFP90. Notably, this FIGURE 1. Systemic lupus erythematosus risk loci in genomic context. The CIRCOS plot [24] shows genes located within the systemic lupus erythematosus risk loci (84 in total) according to their genomic position. The full list of variants and locus genes for this plot is summarized in Supplementary Table 1 ]. Moreover, by using all genotyped single nucleotide polymorphisms (SNPs) (DNA chip) to calculate heritability explained, the explained variation increase to 28% in Chinese patients and 27% Europeans using the GCTA algorithm [32] . Although there are still some uncertainties in the methodology for calculating heritability explained, this shows very strong evidence that we are making progress on the understanding of SLE heritability.
The latest large-scale transancestral study using Immunochip [33 & ], comprising three ancestries: European (6748 cases and 11 516 controls), AfricanAmerican (2970 case and 2452 controls), and Hispanic Amerindian (1872 cases and 2016 controls), have identified nine novel loci for European (TMEM39A-TIMMDC1, DGKQ, LRRC16A, SLC17A4, OLIG3-LOC100130476, GTF2IRD1-GTF2I, FAM86B3P, PKIA-ZC2HC1A, and GRB2), two for AfricanAmerican (PTTG1-MIR146A and PLAT) and two for Hispanic Amerindian (GALC and CLEC16A). By comparing results across different populations, both ancestry-dependent and ancestry-independent contributions to SLE risk are identified with the caveat of unequal cohort sizes. The study reveals evidence of sharing of genetic risk loci between ancestries as well as evidence that each individual population carries unique genetic risk factors at the locus level and at the allelic level.
Missing heritability
In summary, the chip heritability identified by the latest GWAS have explained around 28% of the disease heritability: a marked improvement on 8.3% calculated in 2011 [30] . Although the overall heritability of complex disease is complicated to estimate, a study in European population from a family survey did estimate a heritability of 66 AE 11% for SLE [34] , indicating there are more than 50% of missing heritability in SLE from current GWASs. If we assume that the total heritability is 43.9% (with 25.8% for shared environmental factors) estimated from a Taiwanese population [4] , there is still onethird of heritability left to explain. Explanations for the missing heritability, including larger numbers of variants of smaller effect, rarer variants (possibly with larger effects) that are not present on genotyping arrays or structural variants poorly captured by existing arrays, as well as epigenetic modifications, have been suggested [35] . Innovations in genotyping and sequencing technologies, like the Immunochip platform [18 & ,33 & ] and next-generation sequencing (NGS, as described below) will advance the investigation into common and rare variants and potential effects on the immune system, enhancing our understanding of the genetic risk of SLE.
The linkage disequilibrium that exists in the human genome facilitates the mapping of risk loci by reducing the number of genetic variants required for GWAS; however, the same correlation between genetic polymorphisms at these susceptibility loci then bedevils attempts to identify the actual causal allele(s) at risk loci. Bayesian fine mapping approaches had been proposed to derive smaller sets of SNPs (termed 'credibility sets') as the most likely causal variants at risk loci [36] . Nevertheless, statistical methods are inadequate to fully resolve the problem caused by linkage disequilibrium. To further pursue likely causal SNPs within any given credibility set, the functional effect of SNPs can be studied in silico. As the majority of variants within causal credibility sets are noncoding [37, 38] , function is inferred using gene transcript expression data and epigenetic modification data (as described below) (Figs. 3 and 4) .
APPLICATION OF EXPRESSION QUANTITATIVE TRAIT LOCI MAPPING TO GENOME-WIDE ASSOCIATION STUDIES RESULTS
Assisted by dense genome coverage of the reference panel from the 1000 Genome project [39] , imputation and Bayesian inference provided evidence for missense variants underpinning association for eight genes, including PTPN22, FCGR2A, NCF2, IFIH1, WDFY4, ITGAM, PLD2, and TYK2 [11 & ]. However, as mentioned above, the majority (85-90%) of disease associated loci in SLE are located outside of protein-coding regions, and so might exert their function through altering gene expression rather than by altering protein structure. Of note, an overrepresentation (n ¼ 16) of transcription factors among the 43 SLE susceptibility genes have been annotated in our recent European GWAS [11 & ], further indicating that perturbed gene regulation was a major functional risk factor for SLE. Expression quantitative trait loci (eQTL) mapping, which combines genome-wide expression profiling and genome-wide marker-based genotyping, takes advantage of the heritability of gene expression profiles to identify genetic variants that correlate with changes in gene expression. eQTL can be classified as 'in cis' (locally) or 'in trans' (at a distance) based on their physical distance from the regulated gene.
Some studies [18 & ,23] used public databases, such as the whole blood eQTL browser (http:// genenetwork.nl/bloodeqtlbrowser/) [40] and tissuespecific Genotype-Tissue Expression (GTEx) portal (http://www.gtexportal.org/home/) [41] , to determine whether the disease-associated SNP is a significant eQTL. Of note, limitations exist when applying eQTL analysis to the GTEx whole blood data sets; for example, we seek eQTL in specific immune cell subsets when studying autoimmune disease. To highlight the potential causal genes at the susceptibility loci robustly, it is essential to integrate the disease association and eQTL data using a colocalization approach. That is, to establish that the same genetic variants that underlie the disease association also underlie the eQTL. The presence of linkage disequilibrium in the genome can readily obfuscate this overlap. Colocalization methods, like the regulatory trait concordance (RTC) [42] , conditional analysis [32] , and Bayesian colocalization [43] , can be employed to infer that the disease association and eQTL have the same allelic basis. As many variants have weak eQTL effects, erroneous conclusions will be made if analyses for colocalization are not performed. An example of colocalization analysis of eQTL and GWAS is shown in Fig. 3 [45] . However, eQTL and RTC analyses suggest that SOCS1 (Suppressor of Cytokine Signalling 1) is more likely be a causal gene at the locus (eQTL FDR 0.01 & RTC score !0.9). Moreover, the Odhams et al.'s study [44 & ] illustrated the benefits of using RNA-seq as opposed to microarrays for eQTL mapping, due to more informative data generated by RNA-seq. With RNA-seq, transcript profiling can be done on the gene-level, exon-level, and splice-junction-level, which is more effective in explaining potential regulatory mechanisms.
Nevertheless, we believe that many eQTLs related to SLE risk alleles remain unidentified, data from diverse stimulations and time points will be required, as well as gene expression data from patient material, to reveal the full eQTL landscape of SLE genetics. 
EPIGENETICS TO ANNOTATE FUNCTIONAL/REGULATORY VARIANTS
An approach that is complementary to eQTL analyses to examine the regulatory function of noncoding genetic variants is to study gene regulation with epigenetics. Epigenetic modifications, a term coined to describe genome-wide chromatin modification, including DNA methylation, histone modifications, chromatin accessibility, microRNA regulations, and two-dimensional chromatin interactions [46] , constitute an additional layer of genomic regulation and may serve as a dynamic link between genotype and phenotype. Such changes in DNA and chromatin structure correlate with changes in chromatin accessibility and transcription factor binding. (Fig. 3) . rs922483 overlaps H3K27ac in all three cell types while it overlaps the H3K9ac peak in B cells only. Furthermore, rs922483 is in strong linkage disequilibrium (r 2 ¼ 0.98) with rs2736340, indicating that there is transitive evidence due to the linkage disequilibrium that rs922483 is also associated with systemic lupus erythematosus and is an expression quantitative trait loci. Therefore, rs922483 is the most likely functional SNP in this risk locus.
Genetic advances in systemic lupus erythematosus Chen et al.
The Encyclopedia of DNA elements (ENCODE) project (https://www.encodeproject.org/) [47] has systematically mapped regions of transcription, transcription factor association, chromatin structure and histone modification, and assigns biochemical functions for 80% of the genome, in particular outside of the protein-coding regions. Overall, the project has provided an expansive resource to define the functional DNA elements for biomedical research, whereas the available cell types or cell lines are limited. The cells of closest immune relevance in ENCODE Tier 1 and Tier 2 are LCLs (GM12878), B cells (CD20þ), and monocytes (CD14þ), as well as T cells (CD4þ) and peripheral blood mononuclear cell in Tier 3. A recent Immunochip study in Asians [18 & ] took advantage of ENCODE data to map the underlying loci. For example, one of the signals (rs73366469) identified in this study was located between two 'general transcription factor' genes, GTF2I and GTF2IRD1. By integrating the ENCODE data, they found that an indel SNP rs587608058 (r 2 ¼ 0.81), $1000 bp from rs73366469, lay within conserved enhancer, active chromatin and transcription factor binding sites in LCLs and CD4þ T cells. In addition, this region was found to overlap the transcription start sites for GTF2I and VCF through chromatin interacting analysis and chromosome confirmation capture (Hi-C) analysis, providing evidence for the potential causal variants and genes at this locus for further study.
The Roadmap epigenomics project (http:// www.roadmapepigenomics.org/) [48 && ] integrated analysis of 111 reference human epigenomes to obtain a comprehensive map of the human epigenomic landscape across a large collection of primary cells (including immune cells) and tissues. This map is extremely useful for studies of genome interpretation, gene regulation, cellular differentiation, genome evolution, genetic variation, and human disease. In our meta GWAS analysis of Chinese and European data [22 & ], the histone modification markers, including acetylation markers (H3K27ac and H3K9ac) and methylation markers (H3K27me3 and H3K9me3), from blood cell types were used to investigate the potential regulatory function of the target risk loci. For example, there are several genes, including SRGAP2, SRGAP2D, IKBKE, RASSF5, EIF2D, and DYRK3, located within AE200 kb of the lead GWAS SNP rs2297550. The GWAS SNP was also found to be a putative eQTL for IKBKE, with the SLE risk allele correlated with reduced expression in CD4þ T cells [49] , CD19þ B cells [50] , and NK cells (data unpublished), but with increased expression in CD14þ monocytes [51] . IKBKE encodes a noncanonical I-kappa-B kinase that is essential in regulating inflammatory responses to viral infection by activating the type I interferon, NF-kB and signal transducer and activator of trnascription signalling pathways, suggesting IKBKE might be the potential causal gene. Moreover, there is an intense histone acetylation peak around the associated SNP rs2297550, indicating that rs2297550 may be a potential causal variant [22 & ]. Figure 4 shows an example of fine mapping causal SNPs by integrating genetics and epigenetics.
Another recent completed large-scale epigenomic project, the Blueprint project (http://www. blueprint-epigenome.eu/) [52,53 && ,54 && ], has impressively shown how epigenetic information and analyses can help to study the cellular mechanisms associated with complex human diseases. Moreover, the Blueprint consortium generated three comprehensive reference panels, including genome (whole genome sequencing), transcriptome (RNA-seq), and epigenome (DNA methylation and histone modification), in three immune cells (Neutrophils, monocytes and T cells) from nearly 200 individuals to characterize the contributions of diverse genomic inputs to transcriptional variation. Summary data from these panels can be accessed through http:// blueprint-dev.bioinfo.cnio.es/WP10/.
High-resolution maps of promoter interactions [53 && ] generated by 'Promoter capture Hi-C' (PCHi-C) make it possible to study the long-range regulatory in the three-dimensional nuclear space. By integrating PCHi-C data with disease-associated SNPs generated by GWAS, we can prioritize the putative target genes for the risk loci. The promoter interactomes map may serve as a more robust method to define cis-eQTL rather than by distance, revealing insights into genomic regulatory mechanisms of diseases.
NEXT-GENERATION SEQUENCING IN THE GENOME RESEARCH
With the development of NGS, high-throughput technologies that are now widely used in genome research, any part of the genome can be sequenced. Based on the coverage of the genome, NGS strategies can be classified by scale: target region sequencing, whole-exome sequencing (WES), and wholegenome sequencing (WGS). Targeted resequencing of risk loci in disease cohorts may facilitate the identification of rare variants at common-alleleassociated loci [55] . WES captures all coding exons covering 1-2% of the genome. Nevertheless, as mentioned above, approximately 85-90% of the risk loci associated with SLE are located outside the coding-regions. Compared with WES, WGS can capture the majority of the genome, which facilitates delineation of exon duplications and gene fusions and noncoding regions that might be missing by WES. WGS performs better than WES in the identification of copy number variation and structural variation in the genome which facilitates the identification of coding variants in more complex areas of the genome. However, the higher cost and time consuming bioinformatics analyses that are required to process the data, restrict the application of WGS [56] . In future, with the decreasing cost of sequencing and newly developed computation algorithms, WGS will be increasingly utilized.
Incorporating with a wide range of chromatin profiling experiments, NGS is applied to investigate chromatin biology by identifying genomic loci that are occupied by nucleosomes, bound to transcription factors, or accessible to nuclease cleavage [57] . Technologies such as ChIP-seq [58] , FAIRE-seq, DNase-seq [59, 60] , Hi-C [61] , and ATAC-seq [62] enable genome-wide investigations of a broad range of chromatin phenomena in both qualitative and quantitative ways. Moreover, when introducing NGS to the transcriptome level (RNA-seq), it can be used to detect changes in gene expression, as discussed earlier in this review [40, 63, 64] .
CONCLUSION
Linkage analysis and GWAS studies fail to fully explain disease heritability and do not address the causal nature of risk variants. NGS continues to fuel the discovery of disease-associated common and rare variants. The advances in analysis tools, such as Bayesian fine mapping approaches and high performance computation algorithms, help to make full use of the current massive data to uncover relationships and infer the causality among complex data. Comprehensive sets of functional annotations (ENCODE, Roadmap, and Blueprint projects) in the context of complex genomic structure can be used to predict function and guide experimentation, such as precision genome editing with the CRISPRCas (clustered regulatory interspaced short palindromic repeats/CRISPR-associated) [65, 66] , to address the long standing question of disease mechanism and heterogeneity. Nonetheless, we still have not yet fully exploited analysis of GWAS data, such as genetic studies in non-European populations with different linkage disequilibrium, especially important in SLE given the prevalence; eQTL and epigenetic data in cells from non-European populations for functional annotation; epigenetic data in larger cohorts to look at interindividual variation; eQTL and epigenetic data from disease cohorts, to look for disease specific effects [67 && ]. Studies based on these cohorts will advance our understanding of the disease mechanism, and ultimately speed up the arrival of the era of personalized medicine with genomic data incorporated into diagnosis, prognosis, and treatment in clinics.
